The Claims Defining the Invention are as Follows

1. Use of a combination of oxaliplatin **(OXA)**, leucovorin **(LV)** and 5-fluorouracil **(5-FU)** in the manufacture of a medicament for the treatment of metastatic colorectal cancer in a patient in need of treatment,
    (i) wherein the medicament is to be delivered to said patient on day one of a treatment regime comprising:
        (a) a 2-hour infusion of OXA at a dose of 70 to 80 mg/m^2;
        (b) a 2-hour infusion of LV at a dose of 100 to 400 mg/m^2;
        (c) followed by a bolus of 5-FU at a dose of 300 to 500 mg/m^2 and then an infusion of 5-FU for 40 to 50 hours at a dose of 2.0 to 2.6 g/m^2; and repeating (i),
    (ii) wherein between days 3 to 14 following either the commencement of (i) or following the repeat of (i), selective internal radiation therapy **(SIRT)** is to be delivered to said patient;
    (iii) wherein (i) is to be repeated for three cycles at an interval of one to three weeks between treatment cycles; and
    (iv) wherein two weeks after the final treatment delivered in (iii), said patient is to be delivered the following treatment:
        (a) a 2-hour infusion of OXA at a dose of 80 to 100 mg/m^2;
        (b) a 2-hour infusion of LV at a dose of 100 and 400 mg/m^2;
        (c) followed by a bolus of 5-FU at a dose of 300 to 500 mg/m^2 and then an infusion of 5-FU for 40 to 50 hours at a dose of 2.0 to 2.6 g/m^2.

2. Use of a combination of oxaliplatin (**OXA**), leucovorin (**LV**), and 5-fluorouracil (**5-FU**) in the manufacture of a medicament for the treatment of metastatic colorectal cancer in a patient in need of treatment,
    (i) wherein the medicament is to be delivered to said patient on day one of a treatment regime comprising:
        (a) a 2-hour infusion of OXA at a dose of 60 to 80 mg/m^2;
        (b) a 2-hour infusion of LV at a dose of 100 to 400 mg/m^2;
        (c) followed by a bolus of 5-FU at a dose of 300 to 500 mg/m^2 and then an infusion of 5-FU for 40 to 50 hours at a dose of 2.0 to 2.6 g/m^2; and repeating (i),
    (ii) wherein between days 3 to 14 following either the commencement of (i) or following the repeat of (i), selective internal radiation therapy (**SIRT**) is to be delivered to said patient;
    (iii) wherein (i) is to be repeated for three cycles at an interval of one to three weeks between treatment cycles; and

(iv) wherein two weeks after the final treatment delivered in (iii), said patient is to be delivered the following treatment:

(a) a 2-hour infusion of OXA at a dose of 80 to 100 mg/m^2;

(b) a 2-hour infusion of LV at a dose of 100 and 400 mg/m^2;

(c) followed by a bolus of 5-FU at a dose of 300 to 500 mg/m^2 and then an infusion of 5-FU for 40 to 50 hours at a dose of 2.0 to 2.6 g/m^2.

3. Use of a combination of oxaliplatin (**OXA**), leucovorin (**LV**), and 5-fluorouracil (**5-FU**) in the manufacture of a medicament for the treatment of metastatic colorectal cancer in a patient in need of treatment,

(i) wherein the medicament is to be delivered to said patient on day one of a treatment regime comprising:

(a) a 2-hour infusion of OXA at a dose of 60 to 80 mg/m^2;

(b) a 2-hour infusion of LV at a dose of 100 to 400 mg/m^2;

(c) followed by a bolus of 5-FU at a dose of 300 to 500 mg/m^2 and then an infusion of 5-FU for 40 to 50 hours at a dose of 2.0 to 2.6 g/m^2; and repeating (i),

(ii) wherein between days 3 to 14 following either the commencement of (i) or following the repeat of (i), selective internal radiation therapy (**SIRT**) is to be delivered to said patient;

(iii) wherein (i) is to be repeated for three cycles at an interval of one to three weeks between treatment cycles; and

(iv) wherein two weeks after the final treatment delivered in (iii), said patient is to be delivered the following treatment:

(a) a 2-hour infusion of OXA at a dose of 80 to 100 mg/m^2;

(b) a 2-hour infusion of LV at a dose of 100 and 400 mg/m^2;

(c) followed by a bolus of 5-FU at a dose of 300 to 500 mg/m^2 and a 15 to 90 minute infusion of bevacizumab at 5 to 15 mg/kg, followed by an infusion of 5-FU for 40 to 50 hours at a dose of 2.0 to 2.6 g/m^2.

4. The use according to any one of claims 1-3, further wherein (iv) is to be repeated every 2 to 3 weeks, until the cancer is treated.

5. The use according to any one of claims 1-4, wherein the dose of OXA used in (i)(a) is selected from one of the following OXA doses: 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 mg/m^2.

6. The use according to any one of claims 1-4, wherein the dose of OXA used in (iv)(a) is selected from one of the following OXA doses: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mg/m^2.

7. The use according to any one of claims 1-4, wherein the dose of LV used in (i)(b) or (iv)(b) is selected from one of the following LV doses: 100, 110, 120, 130, 140, 150, 160, 170, 180 and 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400 mg/m^2.

8. The use according to any one of claims 1-4, wherein the bolus dose of 5-FU used in (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500 mg/m^2.

9. The use according to any one of claims 1-4, wherein the infusion dose of 5-FU used in (i)(c) or (iv)(c) is selected from one of the following 5-FU doses: 2.1, 2.2, 2.3, 2.4 and 2.5 g/m^2.

10. The use according to claim 1 or 2, further wherein the patient is to be treated with bevacizumab.

11. The use according to claim 10, wherein bevacizumab is to be administered at a dose of 5 to 10 mg/kg.

12. The use according to claim 11, wherein the bevacizumab is to be delivered to a patient in 30 to 60 minutes.

13. The use according to claim 10, wherein the bevacizumab therapy is to be delivered to said patient in the last cycle of therapy immediately after OXA therapy.

14. The use according to any one of the preceding claims, wherein one or more chemotherapeutic agents additional to those used are incorporated into systemic chemotherapy procedure drugs.

15. The use according claim 14, wherein the chemotherapeutic agents are selected from irinotecan or capecitabine.

16. The use according to any one of the preceding claims, wherein the patient is also to be treated with an anti-angiogenesis factor.

17. The use according to any one of the preceding claims, wherein the patient is to receive an amount of SIRT therapy suitable to effectively treat the cancer.

18. The use according to any one of the preceding claims, wherein the SIRT therapy is to be administered using microparticles.

19. The use according claim 18, wherein the prescribed activity of the microparticles in both lobes of the liver is between 1.2 and 2.4 GBq.